Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim–Chester disease

Zsófia Váradi¹
Rita Bánusz¹
Judit Csomor²
Krisztián Kállay³
Edit Varga¹
Gabriella Kertész¹
Monika Csóka¹

¹Second Department of Pediatrics, ²First Department of Pathology and Experimental Cancer Research, Semmelweis University, ³Pediatric Hematology and Stem Cell Transplantation Unit, United St István and St László Hospital, Budapest, Hungary

Abstract: Erdheim–Chester disease (ECD) is a rare histiocytic disorder, characterized by the xanthomatous infiltration of tissues by CD68-positive and CD1a-/CD100-negative foamy histiocytes. In childhood, ECD is exceptionally rare, and only a dozen cases have been published so far. The cooccurrence of Langerhans cell histiocytosis (LCH) and ECD is even rarer. Here, we report a 2-year-old boy, the youngest patient in the literature so far, who was diagnosed with concomitant BRAF mutation-positive LCH and ECD. In his case, conventional LCH treatment proved to be ineffective, but he is the youngest patient who was successfully treated with the BRAF inhibitor vemurafenib.

Keywords: vemurafenib, treatment, Erdheim–Chester disease, Langerhans cell histiocytosis, pediatric histiocytic disorders

Introduction

ECD is a rare non-Langerhans histiocytic disorder, which typically causes bone lesions, but virtually any organ can be involved, and the presentation symptoms may be also varied, ranging from asymptomatic to multisystem, life-threatening forms. Although, according to the WHO classification, ECD is a neoplasm deriving from CD68-positive and CD1a- and S100-negative histiocytes, the exact pathogenesis has not been fully clarified yet, whether it has a malignant nature or an inflammatory nature.¹ In recent years, a growing number of studies that have investigated the underlying mechanisms of ECD have identified an activating point mutation of BRAF V600E in ~50% of ECD patients. This has given a basis for encouraging targeted therapies. The BRAF inhibitor vemurafenib has demonstrated activity in small cohorts of adults treated with multisystem and refractory ECD.²,³ Data about the usage and efficacy of vemurafenib in pediatric ECD are lacking. We report an excellent therapy response to vemurafenib in a 2-year-old ECD patient, who is the youngest patient in the literature so far.

Case report

A 20-month-old boy was presented with visible soft masses on the left temporal and right parietal bone after a ~1-year-long history of “seborrheic dermatitis” of the...
scalf, “diaper rash”, and recurrent episodes of upper airway infections and otitis media. MRI revealed a $5 \times 5 \times 2.5$ cm size frontal destructive mass on the right, a $6 \times 3 \times 2$ cm size frontotemporoparietal mass, and a $1 \times 1 \times 1$ cm size frontal mass on the left side, and all of them caused bone lesions (Figure 1A and B). Based on the patient history, physical findings, and imaging studies, LCH came up as a possible diagnosis with skin and multifocal bone involvement, which was confirmed histologically: the biopsy specimen from one of the skull masses was histologically composed of

Figure 1 The role of head MRI in the evaluation of therapy response.
Notes: (A) T2W image shows left temporal bone involvement of LCH (white arrow). (B) This lesion shows inhomogenous diffusion restriction (black arrow) on the diffusion-weighted image. (C and D) Normal appearance of the left temporal area after the initial chemotherapy on T2W and diffusion-weighted images. (E and F) Signal abnormality in the left temporal area on the T2W (white arrow) and diffusion-weighted (black arrow) images.
Abbreviations: LCH, Langerhans cell histiocytosis; MRI, magnetic resonance imaging.
CD1a- and S100-positive mononuclear cells with coffee bean-shaped nuclei, eosinophil granulocytes, and multinucleated giant cells (Figure 2A and B). Morphology and immunophenotype were typical for LCH. Furthermore, skeletal manifestations and solid organ involvement were excluded by bone scintigraphy and MRI. We started his chemotherapy based on LCH-III protocol’s appropriate arm, according to the risk of the disease. Thanks to the effectivity of the therapy, rapid regression of the skull masses was detectable in the beginning (Figure 1C and D), but in the fourth month of chemotherapy, hepatosplenomegaly, hypoalbuminemia, serious pancytopenia occurred, the activity of the left frontal bone lesion came back (Figure 1E and F), and the skin symptoms flared up. Bone marrow biopsy was negative at that time. Thereafter, he required dose reduction of cytostatic drugs, his transfusion need was extreme, and he required platelet support almost daily and blood transfusion regularly as well. He required albumin products for severe hypalbuminemia, desferoxamine treatment for secondary hemosiderosis, hospital care almost continuously for frequent septic episodes, and durable heparin therapy for deep vein thrombosis. Due to the serious symptoms, we were forced to stop cytotoxic therapy and started corticosteroid maintenance therapy with indomethacin supplementation for a short period, which was stopped because of its platelet aggregation inhibitory effect and simultaneous gravis thrombocytopenia. Eight months after the initial diagnosis, splenectomy was performed due to symptoms of hypersplenia, and histology confirmed splenic fibrosis represented by multiple fibrohistiocytic nodules composed of foamy macrophages loaded with hemosiderin accompanied by maturing extramedullary hematopoiesis. Bone marrow biopsy at the same time revealed highly similar pathological findings: excessive (~75%) engagement of marrow by CD68-positive and CD1a- and S100-negative macrophages inducing mild fibrosis. These macrophages had water clear wide cytoplasm and rounded nuclei (Figure 3A and B). A significant number of Langerhans cells were not detected in these bone marrow and spleen samples. On plain radiograph of the painful knees, symmetric osteosclerosis could be seen (Figure 4A).
Interestingly, low signal intensities could be seen in all visualized bones (not only in the long bones) on every MRI sequence (Figure 5). These findings raised the diagnosis of non-Langerhans cell ECD with extensive bone marrow and spleen involvement. BRAF V600E mutation positivity was confirmed by pyrosequencing in the initial LCH skull lesion and in the recent ECD bone marrow biopsy specimen as well. According to the diagnosis and the literature, we started IFN-alpha therapy, and then, in default of clinical improvement and after obtaining the result of BRAF V600E mutation positivity of his disease, we stopped IFN-alpha administration and started BRAF inhibitor vemurafenib therapy (according to the license by National Institute of Pharmacy and Nutrition; license number: OGYI/40060-1/2014). As there are no data about the pediatric dosage of vemurafenib, we calculated it by correlating the child’s body surface with the adults’ 2 m² body surface and the associated adult dose (240 mg BID for 0.73 m² body surface). Within a few days, we observed a rapid and impressive improvement in the general state; after 4 days of vemurafenib treatment, his thrombocyte count started to increase, and he did not require transfusions any more. The control bone marrow histological examination after 3 months of BRAF inhibitor therapy showed 60% residual disease, which decreased to 15% in the 11th month. In the 16th month of vemurafenib therapy we could detect complete remission in the bone marrow, which was also verified by BRAF mutation analysis. Our findings reveal that the histological disappearance of the disease from the bone marrow can last for several months; however, the radiological improvement takes a couple of weeks/month (Figure 4B), and the positive clinical response is the first indicator of the effective treatment. This improvement could be seen in a couple of days after starting the vemurafenib therapy.

Now the patient is 4 years old, and he is in the 18th month of vemurafenib therapy given in the same dose.

**Figure 4** Plain radiograph of the knees (A) before and (B) after vemurafenib treatment.

**Notes:** (A) Bilateral, symmetric, irregular sclerotic changes in the metaphysis of the bones. (B) Normal bone structure with a radiolucent band and small cystic lesions next to the epiphyseal plates.

**Figure 5** Coronal T2W image of the spine shows very low signal intensity of the bone marrow that is specific for ECD.

**Abbreviation:** ECD, Erdheim–Chester disease.
from the beginning. His general status is excellent, no hepatosplenomegaly is found, blood count and routine laboratory parameters are normal, and his ECD is in complete remission. The detected side effects of vemurafenib are the lack of eyebrows, very dry, rough skin all over the body, and hypertension.

As there is no experience with the long-term use of vemurafenib in the literature and it can cause serious side effects, regarding the young age and the high-risk disease of our patient, the National Pediatric Stem Cell Transplantation Committee decided to treat him with allogenic stem cell transplantation; hence, the search for an appropriate donor is in progress. Parents’ consent has been obtained for the publication of this case report and its accompanying images.

Discussion

ECD is a rare histiocytic disorder, and since its first description in 1930, ~500 cases have been reported in the literature, and there are only a few publications about pediatric ECD patients. The pathogenesis is still incompletely understood, and there are an increasing number of contradictory results supporting a theory of either a reactive origin or a malignant origin. Recent discovery of the high prevalence of BRAF V600E oncogenic mutation in ECD and LCH but not in other histiocytic disorders suggests that both proliferations could derive from a common origin. In addition to the recognized oncogenic activity of BRAF V600E mutation, it has also been associated with OIS, a recently identified important mechanism against tumor proliferation. As a crucial part of this antitumor activity, BRAFV600E-mutated cells produce a wide range of cytokines and chemokines, and this local inflammatory reaction may prevent the transformation of the mutated cells to cancer. This hypothesis raises the possible rule of OIS in ECD as well. Although ECD can be distinguished from LCH by morphological and immunohistochemical evaluation, based on the same clonal mutations and similar clinical manifestations, the latest updated WHO classification includes them in the same “L” (Langerhans) group. Furthermore, studies suggest that the occurrence of both diseases in the same patient is not rare, and in 12%–20% of patients, they really present as LCH-ECD overlap syndrome. Hervier et al. identified 23 patients with mixed histiocytosis, and both diseases (LCH and LCD) were diagnosed simultaneously in 11 patients (48%). Diagnosis of LCH preceded ECD – similarly to our case – in all remaining patients (52%). To our best knowledge, only one pediatric double diagnosis has been published so far: in 2015, Kim et al. published a case of a 3-year-old boy with intracranial simultaneous LCH and ECD. In these mixed histiocytosis cases, both LCH and ECD bear the same BRAF V600E mutation. These data suggest the theory of the common clonal origin of these disorders.

As ECD is extremely rare in children, evidence regarding treatment is limited to case reports. Successful treatments with corticosteroid monotherapy, IFN-alpha, or anakinra have been published on a case-to-case basis. Since the prognosis of ECD has been reported as poor, search for new therapeutic approaches is essential. More than 50% prevalence of BRAF mutation in ECD patients gives a possible therapeutic target. Clinical experiences with the BRAF inhibitor vemurafenib in ECD are rapidly increasing, both in prospective clinical trials and in “off-label” administration. Initial case reports have demonstrated significant activity of vemurafenib in adult ECD patients: three different publications reported at least partial response following vemurafenib therapy, which involved ~30 ECD patients in all with multisystemic, refractory diseases. In the case of our patient, corticosteroid and IFN-alpha therapies proved to be ineffective, and hence we were forced to change to another therapy option. BRAF mutation positivity of his ECD gave us a potential therapeutic option, which proved to be very effective. Nevertheless, indefinite treatment with BRAF inhibition is potentially unsafe, given the risk of accelerating premalignant RAS-mediated neoplastic lesions, although to date no treatment course has been defined for vemurafenib in ECD. Attempting vemurafenib treatment cession and watch-and-wait attitude were not a real possibility in his case facing with his very high-risk disease. Since 2001, some case reports about autologous stem cell transplantation as a therapy in ECD have been published in the literature, in our case, due to extensive bone marrow infiltration, allogenic transplantation had to be preferred instead of autologous.

Extensive bone marrow involvement in ECD is also not common, but the exact frequency is unknown because of the rarity of the disease, although case reports have been published in 2016 about bone marrow involvement in two adult ECD patients. Recent publication reports the youngest ECD patient in the literature, and this is the first one about the successful application of the BRAF inhibitor vemurafenib in pediatric ECD. The case is also a rarity because of the consecutive presence of BRAF-positive LCH and ECD. Furthermore, according to our encouraging results with this boy, we suggest to think of vemurafenib as a possible, off-label therapy in pediatric ECD.
Acknowledgment
This article was not supported by any financial or other relationships.

Disclosure
The authors report no conflicts of interest in this work.

References